skip to navigation skip to content
 

Accelerate

These ventures have been with Accelerate Cambridge for over three months and are either looking to finalise their product or close their first sales.

angioClast

angioClast is a UK and Ireland-based biotech startup company led by a group of young professionals from the University of Cambridge. We are developing products targeting Glioblastoma Multiforme, the most aggressive and incurable brain cancer, from both diagnostic and therapeutic perspectives. 

angioClast's business model is to license out a patent from the National Institute of Health through the NIH start-up exclusive licensing agreement, and harness the value of newly identified biomarkers of cancer-associated blood vessels. Antibodies against these markers form the basis for antibody-drug conjugates (ADCs) that will deliver and release drugs against glioblastoma in a highly specific manner. Detection of glioblastoma will be made possible through further formulation of the antibodies into an ELISA-based diagnostic toolkit that is more accurate and less invasive than conventional clinical practices.

Through innovative products for early detection and targeted therapy, angioClast's vision is to make Glioblastoma Multiforme a more treatable disease.

Anvil

 Anvil is a tool that takes the pain out of software development, without sacrificing power. Companies are best placed to know their own businesses and develop their own business process tools, but developing web applications is hugely slow and complicated. Anvil's visual designer, simple Python code environment and "batteries-included" philosophy makes business application development faster, easier and more agile.

Visit the Anvil website

AppLapp

AppLapp is a spin-off from the Department of Theoretical and Applied Linguistics with the mission to democratise and streamline the tests for the cognitive development of children. These tests are currently inaccessible to parents, cost speech therapists hundreds of pounds, and take around 30 minutes to happen. We will make these tests accessible to parents and speech therapists and reduce the time to five minutes.

CamBioScience Limited

Since 2015 CamBioScience Limited has provided intensive training courses in breakthrough life science technologies for professionals in academia and industry. To date the company has trained an international customer base of professional scientists from over 50 leading academic and industrial institutions and more than 20 countries worldwide. As of 2017 CamBioScience began scaling-up its capacity to deliver breakthrough course content via the construction of a bespoke cloud-based e-learning platform aimed at disrupting high-tech knowledge acquisition and assessment in the wider life science sectors (biotechnology, bioengineering, biopharma and medtech). By making use of our in-house machine learning capabilities we are able to fully individualise the learning process for high-skilled professionals at the very top of their industries. The CamBioScience team is made up of three PhD trained co-founding directors who are aptly supported by a team of leading software developers and a videographer.

Capito Systems

Capito Systems (est. 2012), also trading as capito.ai, specialises in the contextual understanding of natural language (NLU). We have built a high performance NLU cloud platform that delivers application-specific semantic understanding of free-form voice and text inputs at speed and scale. Applications include intelligent voice control, conversational interfaces like chat bots, and semantic search. Our technology is platform-independent and easy to integrate via our APIs. We are able to ‘bootstrap’ NLU models quickly using the latest machine learning techniques coupled with our streamlined development workflows in support of rapid prototyping & testing. Unlike other NLP/NLU solutions, including the “open developer platforms” offered by major players like Amazon, Microsoft and Facebook, ours is a premium NLU product customised for each use case by our in-house experts, as we seek to develop long-term relationships with our clients. 

Citrecycle

Citrecycle has adapted new technology that unlocks the full potential of the lead-acid batteries (LAB) recycling industry in developing countries whilst simultaneously maintaining focus on development objectives. Citrecycle uses hydro metallurgy to recycle LAB in a safe, clean and sustainable way. We will utilise local independent co-operatives to collect the supply for recycling. Our ability to extract more value from each battery enables us to buy batteries at greater value than that that can be obtained from informal recycling. We can double the amount paid per battery, and still remain profitable, to ensure Citrecycle can absorb the informal recycling sector. Our process then recycles the batteries cleanly, using a Carbon neutral process. Hydro metallurgy inherently restricts poisonous emissions, slashes direct and indirect CO2 and operates profitably at smaller scales, 1000 tons per year rather than 50,000 - the size at which adequate pollution controls are considered to be cost effective. The scalable nature means that small, community directed plants will not replace the informal recyclers industry, but empower local communities by providing a cleaner and safer way to make money through localised employment. The replacement of informal LAB recycling practices with a safe provision that does not involve dangerous emissions, eradicates exposure of local communities and the environment to lead contamination, eliminating the risk of lead poisoning. The need for strong infrastructure for mass collection is overcome, sound legislation is unnecessary to regulate safety and exposure of local communities and the environment to lead contamination is prevented. Pollution, lead poisoning and fatality are replaced by job opportunities, prosperity, cleanliness and health.

info@citrecycle.co.uk

Watch the CitreCycle team in discussion with Luther Phillips

 

 

Citrecycle logo

CrossBridge Scientific

CrossBridge Scientific offers a simple, minimal effort fitness test delivered via a wearable device to measure human thermoregulation. Sweating is an essential physiological response to rises in core body temperature triggered by physical activity and other stressors. Few understand why they sweat or that the sweating response is improved through physical training. CrossBridge Scientific’s analytics platform is powered by aggregated tests of a diverse community to provide insights to the end user, including the impact of a chosen training, or de-training, program and personal capability assessment on event day. CrossBridge Scientific aims to further the scientific theory and physical training impact of the thermoregulation process to advance human achievements in endurance sport.

Intact Digital

Intact Digital, Ltd provides services that sustain the use of software applications and systems beyond their market life-time and ensure that digital content, document, and data can be used in the future. Intact Digital services are delivered through virtualization of legacy software and through transformation of data and document formats for use with contemporary software. They enable enterprises to futureproof their software and content and to support digital continuity in their business operations and innovation strategy. 

INTACT Software platform enables software vendors to host their current and past software in virtual machines and reassure their customers that the software will stay functional and usable beyond its market lifetime. 

INTACT Content assurance augments standard storage services by providing legacy software that is needed to access archived data and content. The legacy software is virtualized and provided 

INTACT Continuity services reduce the risk of disruption and loss during migration and decommission of legacy systems. They provide comprehensive and long term strategy for retaining value of digital assets. 

Intact Digital services can host virtualized legacy software that has been produced and used within the past three decades. The use of virtualized software is enabled remotely, as a cloud service, or locally, as an on-premise installation. Virtualized software applications enable the use of documents, data, and applications in their original form. With Intact Digital conversion services the customer can also extract data and transform document formats for use across different applications and services.

Organizations that need to ensure long term use of digital archives can select Intact Digital Assurance plans to acquire access to the collection of virtualized legacy software required for content access. 

Intact Digital services enable enterprises to extend the value of their IT investment, increase the reliability of compliance procedures, and expand opportunities for innovation through the use of data and tools that would, otherwise, be inaccessible and unusable due to the aging of digital technologies.

Visit the Intact Digital website

JustMilk

JustMilk consists of a US non-profit and a UK for-profit organisation developing the Nipple Shield Delivery System (NSDS), a novel medical device with the potential to improve the safety, efficacy, and access to life-saving medications, vitamins, and nutrients to breastfeeding infants globally. 

When worn by a mother during breastfeeding, the NSDS releases active pharmaceutical agents into milk which is then consumed by the infant. A wide range of medications and nutrients could be delivered to infants for treatment or prevention of conditions which may include diarrhoeal disease, HIV, malaria, or malnutrition.

With the NSDS, JustMilk aims to bridge a global drug delivery technology gap for breastfeeding infants, particularly in developing countries where it could overcome conventional administration challenges associated with limited availability of potable water, refrigeration, and medical care. JustMilk is currently seeking pharmaceutical partners.

Watch JustMilk in discussion with Luther Phillips

Visit the JustMilk website

JustMilk logo

nūfood

Our multidisciplinary team has been hard at work for the past two years perfecting nūfood: a kitchen robot which enables foodies and creative chefs to 3D print 'flavour bursts'; intense taste sensations to accompany any meal or cocktail on demand. Used in conjunction with pre-mixed sauces the product offers endless possibilities for shape, flavour and texture. Sweet and savoury ‘flavour bursts’ are designed with our easy to use mobile app and printed in a few short minutes. Currently the star of unique pop-up dining events across Europe, we look forward to introducing the possibilities of nūfood to a wider audience.

Visit the nūfood website

PHARMeNABLE

The rise of antibiotic resistance is one example of the need for new medicines; however, the pharmaceutical industry is facing a downturn in drug discovery success with shrinking pipelines and blockbusters coming off patent despite enormous amounts of money being spent on drug discovery every year ($1.5 bn).

One solution for discovering new medicines is by finding innovative ways to generate new leads and provide a much-needed boost to the early drug discovery process, which can feed into industry pipelines. Academic research groups around the world possess thousands of under-tested and under-utilised compounds and although these get published in journals the journey for the compounds often ends there, as they are often only tested against a handful of biological targets and rarely applied any further.

At PHARMeNABLE we will initially use the Spring research group’s unique compound library in conjunction with the multi-target screening programme developed by the Bender group, to identify novel hit compounds and eventually leads against the most challenging biological targets. The discovery of these initial hits could lead to the development of next-generation therapeutics, for example, a novel antibacterial agent or a much needed cancer treatment.

Satavia

 Satavia is an analytics and visualisation company that develops bespoke environmental awareness solutions for all segments of the aviation market. We aim to provide ‘personalised environmental health management’ for aircraft and unmanned aerial systems to reinforce the safety and reliability of flight operations, while minimising unanticipated maintenance costs. Satavia delivers live aircraft-centric metrics for a range of environmental threats and combines expertise in aeronautical meteorology, big data and analytics, and 3-D visualisation technology.

Swift Molecular Diagnostics

Swift Molecular Diagnostics have created a novel technology that allows the development of self-contained diagnostic devices for the fast, accurate and low-cost genetic detection that do not require laboratory facilities or trained personnel.

We have filed the patent application of our technology and we aim in the first instance to implement our technology to detect antibiotic resistance from patients, allowing the effective treatment of bacterial infections and fast response in acute cases such as bacteraemia and septicaemia.

Watch the Swift Molecular Diagnostics team in discussion with Luther Phillips

SwiftDX

Vocalens

Vocalens is a Cambridge University spin-out startup developing smart wearable assistive technology for people with visual impairment. The company is headquartered in Cambridge, UK and co-founded by two engineers and Cambridge MBAs.

Xcan Net

Xcan Net provides software and a cloud-based solution that enables doctors to analyse X-ray images more quickly and accurately. We use neural networks (a machine learning technique) to rank images by their severity and highlight potentially dangerous features to radiologists. Our system offers an effective solution to tackle the increasing demand on X-ray image reporting and the large shortage of radiologists across the world. The Xcan Net team has medical, programming as well as consulting expertise.